| value |
{"aggregator_url":"https://www.sec.gov {"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1708599/0001708599-26-000027.txt","as_of":"2026-04-22T03:03:32.063787+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1708599/0001708599-26-000027.txt","company":"Serina Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1708599/0001708599-26-000027.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_70c323f1994525e4","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1708599/0001708599-26-000027.txt","content_type":"text/plain","enriched_at":"2026-04-22T03:31:42.805455+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"ser-20260415","final_url":"https://www.sec.gov/Archives/edgar/data/1708599/0001708599-26-000027.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1708599/0001708599-26-000027.txt","source_event_id":"evt_e27d952072d9","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"a9efd81e9cf921ad","kind":"sec_filing","published_at":"20260421","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.72,"dates_mentioned":["2026-04-22T03:03:32.063787+00:00","20260421"],"entities":[{"asset_class":"equity","name":"Serina Therapeutics, Inc.","relevance":"high","symbol":"","type":"issuer"},{"asset_class":"law","name":"Delaware General Corporation Law (DGCL)","relevance":"medium","symbol":"","type":"legal_framework"},{"asset_class":"law","name":"Securities Exchange Act of 1934 (Rule 14a-8)","relevance":"medium","symbol":"","type":"legal_framework"}],"event_type":"other","information_gaps":["What specific changes were made versus the prior known bylaws version is not explicitly stated in the provided text (no redline/diff or prior-version comparison included).","The 8-K \u201cmaterial items\u201d (e.g., which Item number(s) the bylaws relate to) are not provided in the extracted content.","The filing date shown in the structured context (2026-04-22T03:03:32.063787+00:00) and the source summary date (20260421) are not reconciled in the text excerpt.","The excerpt appears truncated mid-sentence in Section 3.2(b)(iii) (ends at \u201cfailure to rece\u201d), so any remaining procedural requirements are missing."],"key_facts":["The document in the filing is labeled \u201cAMENDED AND RESTATED BYLAWS OF SERINA THERAPEUTICS, INC. (A DELAWARE CORPORATION).\u201d","Article 1 sets the corporation\u2019s registered office in Dover, Delaware (County of Kent) and allows other offices as fixed by the Board of Directors.","Article 2 provides that the Board of Directors may adopt a corporate seal and describes its inscription (\u201cCorporate Seal-Delaware\u201d).","Article 3 Section 3.1 allows stockholders\u2019 meetings to be held at a place determined by the Board or, if not designated, at the principal offices; it also allows the Board to hold meetings solely by remote communication as provided under the DGCL.","Article 3 Section 3.2(a) describes annual meeting timing as designated by the Board/committee and limits business to matters properly brought under the DGCL and the bylaws\u2019 procedures.","Article 3 Section 3.2(a) includes an \u201cexclusive means\u201d clause stating that clause (iii) is the exclusive means for a stockholder to make nominations and submit other business (subject to exceptions for matters included in the notice/proxy framework and Rule 14a-8).","Article 3 Section 3.2(b) sets procedures for stockholder notice to the Secretary for nominations, including requirements to deliver written notice and update/supplement information timely (details shown for nominee information)."],"numeric_claims":[],"primary_claim":"The 8-K filing by Serina Therapeutics, Inc. includes amended and restated bylaws for the Delaware corporation, with provisions addressing registered office, corporate seal, and stockholders\u2019 meeting procedures (including remote communication).","relevance_score":0.45,"sentiment":"neutral","source_quality":"high","summary":"Serina Therapeutics, Inc. filed a Form 8-K that includes an amended and restated version of its Delaware bylaws. The provided text reflects changes/restatement covering corporate governance provisions such as offices, corporate seal, and stockholders\u2019 meeting procedures (including remote meetings).","topics":["SEC filing","8-K","amended and restated bylaws","corporate governance","stockholders\u2019 meetings","remote communication","Delaware corporation bylaws"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 Serina Therapeutics, Inc. \u00b7 Filed 20260421","ticker":"SER","tickers":["SER"],"title":"SER filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/1708599/0001708599-26-000027.txt"}... |